Immunis, Inc., a clinical-level biotech establishing creative stem cell empowered biologics for disease and age-based immune dysregulation, has officially published peer-reviewed research in partnership with Dr Micah Drummond from the University of Utah. The discovery published in obesity is named “Stem Cell Secretome Treatment Reduces Adiposity and Improves Glucose Handling During Obesity and Weight Loss in Mice.” The study further confirms its position with the comprehensive efforts.
According to the reports fetched by the National Center for Health Statistics, the percentage of Americans aged 65 and above with obesity has increased by 40% for women and men. On the other side, the pharmacotherapies such as GLP-1 receptor agonists have achieved global commercial progress for their potential to succeed in rapid weight loss by 25-40% of the total reduction from these drugs has shown an alleviation in lean muscle, not fat. There is a crucial requirement for pharmaceuticals that can promote fat loss precisely without sacrificing muscle health.
The Immunis’ publication opens about the effects of its investigationally addressed therapeutic, the IMM01-STEM, in the aged mice models of obesity. The major findings include IMM01-STEM’s improvement contribution in weight loss in obese mice by mitigating the volume of whole body fat while elevating the lean mass. Secondly, it also reversed fibrosis and liver steatosis in aged mice following a high-fat diet to match similar to that of healthy controls.
The findings also involve IMM01-STEM’s preservation ability of muscle mass and improvement of muscle quality by doubling the muscle fiber size, reducing fibrosis and elevating blood capillary. Alongside, IMM01-STEM delivers crucial metabolic benefits during the weight loss period that stimulate the glucose tolerance level and reduce fasting insulin levels, with qualified mice succeeding over metabolic profiles matched to healthy controls.
These key findings data commits basis on the integrated investigations of IMM01-STEM in contributing to tissue and metabolic health during weight loss and obesity in humans. This research has commendably co-anchored the study from Immunis’s two more published preclinical studies, named Aging Cell and GeroScience.
The Immunis’ Chairman and publication author, Dr Hans Keirstead, said, “Publishing in a known scientific journal like Obesity reiterates the value of our team’s research initiative. IMM01-STEM might transition human healthspan by announcing a healthier form of weight loss. We are grateful to discover the benefits of our effective drug when the healthspan therapies are in form.”
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
